From Lab Bench to EU Funding: Maurizio Aiello’s Story
React4life provides cancer researchers with cutting‑edge tools to study tumour progression. Thanks to strategic EU programmes, the company has moved from a modest laboratory project to a recognised biotech delivering commercial assays. Earlier this year our CEO, Maurizio Aiello, sat down with Teresa De Martino, Scientific Officer of the European Commission, for the feature “Interview with a FET Innovator in the service of oncology patients.”
A career built on curiosity, resilience and leadership
Maurizio began his academic journey at the historic Scuola Militare Nunziatella, later earning a doctorate in nuclear physics (summa cum laude). After gaining experience in insurance sales, pharmaceutical modelling, and defence systems, he founded a cybersecurity spin‑off for Italy’s National Research Council.
In 2016 he co‑founded React4life with Silvia Scaglione. By October 2018 he had taken the helm as CEO, guiding the company through accelerator programmes, early‑stage funding rounds and a rapid product‑development cycle. Today, React4life operates with a mature management team, a growing portfolio of commercial assays, and a steady pipeline of innovation projects.
